Description
Inhalable nanostructured microparticles of simvastatin, a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor, were rationally designed for targeted pulmonary delivery as dry powder inhalers (DPIs) for the treatment of pulmonary hypertension (PH). Advan...
| Date made available | 2021 |
|---|---|
| Publisher | SAGE Journals |
Research output
- 1 Article
-
Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization, in vitro 2D/3D human lung cell cultures, and in vivo efficacy
Acosta, M. F., Muralidharan, P., Grijalva, C. L., Abrahamson, M. D., Hayes, D., Fineman, J. R., Black, S. M. & Mansour, H. M., 2021, In: Therapeutic Advances in Respiratory Disease. 15Research output: Contribution to journal › Article › peer-review
Open Access12 Link opens in a new tab Scopus citations
Cite this
- DataSetCite